KTOV - Kitov Pharma Ltd

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.717
+0.007 (+0.26%)
As of 9:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.710
Open2.770
Bid2.750 x 1800
Ask2.790 x 800
Day's Range2.700 - 2.770
52 Week Range1.270 - 3.810
Volume51,739
Avg. Volume571,434
Market Cap42.957M
Beta2.26
PE Ratio (TTM)N/A
EPS (TTM)-1.300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Kitov Announces Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy

    Kitov Pharma Ltd. (KTOV) (KTOV.TA), an innovative biopharmaceutical company, today announced positive results in a pre-clinical study testing NT219, a first-in-class small molecule targeting IRS1/2 and STAT3, two signal proteins that are part of an anti-cancer drug resistance mechanism. The study, conducted by Kitov’s majority-owned subsidiary, TyrNovo Ltd., evaluated NT219 in combination with gemcitabine in a patient-derived xenograft (PDX) model of pancreatic cancer and was conducted in accordance with guidance from the U.S. Food and Drug Administration (FDA). NT219 was tested at three dose levels in combination with gemcitabine vs. gemcitabine alone.

  • GlobeNewswire19 days ago

    Kitov Announces Pricing of $8,150,000 Registered Direct Offering

    TEL-AVIV, Israel, June 01, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors providing for the issuance of 3,260,000 American Depositary Shares (ADS) at a purchase price of $2.50 per ADS in a registered direct offering. Kitov will also issue unregistered warrants to purchase up to 1,630,000 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 14, 2016.

  • ACCESSWIRE19 days ago

    Today’s Research Reports on Stocks to Watch: Kitov Pharma and Clearside Biomedical

    NEW YORK, NY / ACCESSWIRE / June 1, 2018 / It was FDA news that sent shares of Kitov Pharma blasting off on Thursday. Shares of Clearside Biomedical sunk despite positive topline results being announced ...

  • GlobeNewswire20 days ago

    FDA Approves Kitov’s Consensi™ for Treatment of Osteoarthritis Pain and Hypertension

    TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Consensi™ (amlodipine and celecoxib) oral tablets for marketing. Consensi™ is a patent-protected combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and amlodipine besylate, an antihypertensive calcium channel blocker. Consensi™ was approved for once daily use in three dosage forms, corresponding to the current approved dosages of amlodipine (2.5, 5, and 10 mg) for hypertension and a 200 mg dose of celecoxib for the treatment of osteoarthritis pain.

  • ACCESSWIRElast month

    Wired News – Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Kitov Pharma Ltd (NASDAQ: KTOV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KTOV as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a definitive license and commercialization deal with China-based Hebei Changshan Biochemical Pharmaceutical Co., Ltd ("Changshan"), granting the latter exclusive rights to import, manufacture, and distribute the Company's lead drug candidate, Consensi™, in China.

  • GlobeNewswirelast month

    Kitov Announces Consensi™ Commercialization Agreement for China

    TASE: KTOV), an innovative biopharmaceutical company, announced today that the Company has signed a definitive license and commercialization agreement for the Chinese market, granting exclusive rights to import, manufacture and distribute its lead drug candidate, Consensi™, in China to Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharma), a Chinese public company traded on the Shenzhen Stock Exchange. Consensi™, formerly known as KIT-302, is a combination drug intended to simultaneously treat pain caused by osteoarthritis, and hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain. Consensi™ is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure.

  • PR Newswire2 months ago

    TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research

    TEL AVIV, Israel, April 13, 2018 /PRNewswire/ -- Kitov Pharma (NASDAQ and TASE: KTOV), today announced that TyrNovo Ltd., a company majority-owned by Kitov, will present pre-clinical data on TyrNovo's anti-tumor resistance drug candidate, NT219, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2018, to be held on April 14-18, at the McCormick Place, Chicago, Illinois.

  • PR Newswire3 months ago

    TyrNovo to Present at BIO-Europe Spring® 2018 Conference

    TEL AVIV, Israel, March 8, 2018 /PRNewswire/ -- Kitov Pharmaceuticals (KTOV) (KTOV), an innovative biopharmaceutical company, announced today that Dr. Gil Ben-Menachem, VP Business Development of TyrNovo, a Kitov Pharmaceuticals company, will present recent results from pre-clinical studies with NT219, a novel dual inhibitor of STAT3 and IRS1/2, at the 2018 BIO-Europe Spring® Conference at the RAI Convention Center, in Amsterdam, The Netherlands. NT219 is an innovative, unique small molecule targeting IRS1/2 and STAT, two signal proteins that are part of an anti-cancer drug resistance mechanism.

  • PR Newswire4 months ago

    Kitov Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to Shareholders

    TASE: KTOV), an innovative biopharmaceutical company, announced today that it filed its Annual Report for 2017 on Form 20-F, including its full financial results for the year ended December 31, 2017. Consensi™, a combination drug that simultaneously treats pain caused by osteoarthritis and treats hypertension, is comprised of two FDA approved drugs, celecoxib (Celebrex®), an NSAID, for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a drug designed to treat hypertension.

  • PR Newswire6 months ago

    Kitov Announces Consensi™ as Brand Name for KIT-302

    "The receipt of the FDA's permission to use Consensi as the brand name for our lead drug is another important step in executing on our corporate strategy and will facilitate the commercialization of KIT-302, once approved by the FDA, " stated J. Paul Waymack, M.D., Sc.D., Kitov's Chairman of the Board and Chief Medical Officer. Consensi™ is a combination drug that is intended to simultaneously treat pain caused by osteoarthritis, as well as hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain.   Consensi™ is comprised of two FDA approved drugs, celecoxib (Celebrex®), a COX-2 inhibitor, for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure.

  • PR Newswire8 months ago

    Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package

    TASE: KTOV), an innovative biopharmaceutical company, announced today that it has received the U.S. Food and Drug Administration's (FDA) response to the NT219's pre-IND meeting package.  FDA has agreed to the proposed Chemistry Manufacturing and Controls (CMC), preclinical, and clinical development plans for NT219. For the clinical development plan, the FDA agreed with TyrNovo's proposed development plan to test NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer.

  • PR Newswire8 months ago

    Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function

    TASE: KTOV), an innovative biopharmaceutical company, announced today that its randomized double-blind, placebo-controlled renal function clinical trial for its lead drug candidate, KIT-302, successfully met its primary efficacy endpoint. Data from the trial demonstrated that KIT-302 lowered systolic blood pressure a comparable amount to the widely used antihypertension drug, amlodipine besylate, thus meeting the trial's primary efficacy endpoint of achieving at least 50% of the amlodipine reduction (p=0.019).

  • PR Newswire8 months ago

    Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock

    - Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS. - NT219 is a first-in-class drug candidate presenting a new paradigm of cancer treatment - overcoming tumors' cancer drug resistance. TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the acquisition of an additional 27% stake in TyrNovo Ltd., a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders.  As announced on January 13, 2017, Kitov had acquired a controlling interest, which is now approximately 65% of TyrNovo.  After the closing of this transaction, Kitov will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares.

  • ACCESSWIRE9 months ago

    Corporate News Blog - US FDA Accepts Kitov Pharma’s Lead Drug Candidate for Full Review

    LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Kitov Pharmaceuticals Holdings Ltd (NASDAQ: KTOV ), following which we ...

  • PR Newswire9 months ago

    Kitov Announces Filing by FDA of New Drug Application for KIT-302

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) filed the Company's New Drug Application (NDA) for KIT-302, its lead drug candidate, thereby accepting the NDA for a full review. KIT-302 is a patented combination of celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously.

  • PR Newswire10 months ago

    Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results

    TEL AVIV, Israel , Aug. 16, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported ...

  • PR Newswire11 months ago

    Kitov Submits New Drug Application to FDA for KIT-302

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KIT-302, its lead drug candidate. KIT-302 is a patented combination of celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously. The company expects that within 60 days the FDA will determine whether the NDA is complete and acceptable for filing.

  • PR Newswire11 months ago

    Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model

    TEL AVIV, Israel, July 18, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (KTOV), an innovative biopharmaceutical company, today announced  results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo Ltd., in combination with Keytruda®, converted non-responding tumors to responders and blocked tumor progression in an immune-oncology preclinical model. The study, conducted in collaboration with researchers at Bar Ilan University and Rabin Medical Center, assessed NT-219's ability to overcome cancer drug resistance in a patient-derived xenograft (PDX) model of immune-deficient mice, in which a tumor originated from an esophagus cancer biopsy was implanted.

  • PR Newswire11 months ago

    Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering

    Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that it has entered into definitive agreements with institutional and other investors providing for the issuance of 2,431,746 American Depositary Shares (ADS) at a purchase price of $1.45 per ADS in a registered direct offering. Kitov will issue unregistered warrants to purchase up to 1,215,873 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission  (the "SEC") on December 14, 2016.

  • Benzinga11 months ago

    Kitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on Board

     Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ) is announcing that on July 6, 2017 the Board of Directors (the “Board”) of the Company determined to fill a vacancy on the Board, and to appoint Gil ...

  • PR Newswirelast year

    Kitov Updates on KIT-302 New Drug Application

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that it has begun the process of digitizing its New Drug Application (NDA) for KIT-302, its lead drug candidate, through Parexel International Corporation, a clinical research organization, which has been engaged by Kitov for the preparation of the NDA into the standard, accepted electronic format of the U.S. Food and Drug Administration (FDA). KIT-302 is Kitov's patented combination of celecoxib and amlodipine, is intended to treat osteoarthritis pain and hypertension simultaneously.